



## Cancer Control Program Health Disparities Committee

200 First Street, SW  
Rochester, MN 55905  
P: 507-266-9202  
F: 507-284-1803

[www.allianceforclinicaltrialsinoncology.org](http://www.allianceforclinicaltrialsinoncology.org)

Electra Paskett, Ph.D.  
Chair

### Agenda Health Disparities Committee Meeting Saturday, May 10, 2014 8:00-10:00 AM CST

**Meeting available by teleconference: Dial 800-501-8979 Access Code: 7029171**

**Meeting available by webconference: log into [www.paetec.com/conferencing](http://www.paetec.com/conferencing), click on the "Join a Conference" option, enter 8005018979 followed by the 7-digit access code: 7029171. You will be asked to enter your name, email, phone and company. Only the name is required.**

<b>Committee Members:</b>		
Electra Paskett, PhD (Chair)	Lucy Gansauer, RN, MSN, CPS	William S. Loui, MD
Judith S. Kaur, MD (Co-vice Chair)	Sarah Gehlert, PhD	Elena Martinez, PhD, MPH
Gary W. Unzeitig, MD (Co-vice Chair)	Christopher C. Goulet, MD	Phyllis Nassi
Lucile L. Adams-Campbell, PhD	Bettye Green	Gilbert Padula, MD
James N. Atkins, MD	Mary Helen Hackney, MD	Ann H. Partridge, MD
James D. Bearden III, MD, FACP	Kent Hoskins, MD	David J. Peace, MD
Jeffrey L. Berenberg, MD	Anand P. Jillella, MBBS	Blase N. Polite, MD
A. William Blackstock, MD	Mira L. Katz, PhD, MPH	Douglas M. Post, PhD
Jan C. Buckner, MD	M. Margaret Kemeny, MD	Paul L. Reiter, PhD
Elizabeth (Beth) Calhoun, PhD	Anita Y. Kinney, PhD	Ivis Sampayo
Alison K. Conlin, MD, MPH	Rick Kittles, PhD	Terence Sio, MD
Timothy P. Cooley, MD	Jacqueline M. Lafky, MS	Gamini S. Soori, MD
Zoneddy R. Dayao, MD	A. Marilyn Leitch, MD	John Taylor, MA
Deborah Erwin, PhD	Sharon G. Levy, RN, BSN	Margaret E. White, RN, OCN, CCRP
Anu Goel Gaba, MD	Jennifer A. Ligibel, MD	Yousuf Zafar, MD

#### I. Welcome

#### II. Scientific Presentations (15 minutes each)

- A. Presentation on the National Cancer Data Base (NCDB) (*Greer Gay, RN, PhD, MPH*)
- B. New Concepts
  1. Promoting Risk-appropriate Colorectal Cancer Screening in Family Members of Colorectal Cancer Patients: A Pragmatic Stepped Care Randomized Controlled Trial (*Anita Kinney, PhD*)
  2. Modified ACT Model for Developing and Implementing Tailored Interventions to Reduce Participation Disparity (*Mira Katz, PhD, MPH*)
  3. Improving Outcomes among Head and Neck Cancer Patients through Navigation (*Lucy Gansauer, RN, MSN, CPS*)

#### III. Study Update Presentations (10 minutes each)

- A Tailored Patient-Centered Communication Intervention for Breast Cancer Patients Undergoing Chemotherapy (Doug M. Post, PhD)
- Testing In and Out-of-visit Surgical Decision Aids for Minority Men Diagnosed with Prostate Cancer (Jon C. Tilburt, MD)

- Cancer Mortality in American Indians and Alaskan Natives (Judith Kaur, MD)

#### **IV. Working Group Updates (10 minutes each)**

- A. Research (Paul Reiter, PhD)
- B. Data Collection (Blase Polite, MD)
- C. Education and Training (Bettye Green)
- D. Outreach and Accrual (Judith Kaur, MD)

#### **V. Study Tracker Review (remaining time)**



ALLIANCEStudyTracker\_HDC\_01Nov2013.

##### **A. Concepts in Development**

1. On Hold: Waiting for data to mature
  - Race-based Outcome Differences in Obese DLBCL Patients (Kenneth Carson, MD)
  - Age and Outcomes Disparities Across CALGB & NCCTG Adjuvant Breast Trials with HER2 and Grade Data Available (Ann H. Partridge, MD)
  - Analyses of Disparate Outcomes in Former CALGB Studies and BMI (Ann H. Partridge, MD)
  - Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Breast Cancer (Jennifer Ligibel, MD)
2. Still in Discussion Phase:
  - Randomized Trial of Exercise Training on Progression-Free Survival in Newly Diagnosed Inoperable NSCLC (Lee W. Jones, PhD)
  - Evaluation of Ancestry Information Markers (AIMs) from previous ACOSOG/CALGB/NCCTG Trials (Rick Kittles, PhD)

##### **B. Closed Studies**

- Quality of life of African-American cancer survivors (Carol Ferrans)
- A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound NAB - paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (Hope Rugo, MD)
- A Meta Analysis of QOL Differences by Race in Patients on NCCTG and Mayo Trials (Jeff Sloan, PhD)

#### **VI. Notation Only: Health Disparities Publications Since November 2013**

#### **VII. Upcoming Meeting(s)**

Next HDC Meeting, Tuesday June 3, 2014, 2:00 EST/1:00 CST

#### **VIII. Other Business**